Schneeweiss, A., Albanell Mestres, J., & Cervantes, A. (2018). Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
Citación estilo ChicagoSchneeweiss, Andreas, Joan Albanell Mestres, y Andrés Cervantes. Phase Ib Study Evaluating Safety and Clinical Activity of the Anti-HER3 Antibody Lumretuzumab Combined With the Anti-HER2 Antibody Pertuzumab and Paclitaxel in HER3-positive, HER2-low Metastatic Breast Cancer. 2018.
Cita MLASchneeweiss, Andreas, Joan Albanell Mestres, y Andrés Cervantes. Phase Ib Study Evaluating Safety and Clinical Activity of the Anti-HER3 Antibody Lumretuzumab Combined With the Anti-HER2 Antibody Pertuzumab and Paclitaxel in HER3-positive, HER2-low Metastatic Breast Cancer. 2018.